Clinician Scientist Supporting NCI-funded Clinical Trials at the Medical College of Wisconsin Cancer Center

项目总结 这个应用程序为一位非常有成就的临床试验专家寻求部分工资支持。 在威斯康星医学院(MCW)癌症中心。迈赫迪·哈马达尼，医学博士，申请人 研究专家奖，现任医学教授兼医学和行政主任 癌症中心的临床血液和骨髓移植及细胞治疗计划(BMT/CT)。作为一名 每周两天到恶性血液病门诊和七到八周的临床医生 每年住院期间，Hamadani的做法包括大约700名活跃的癌症患者，以及147名新患者 2021年，他向他的临床患者提供了49次骨髓移植和CT检查。同时，哈马达尼也是一个 癌症中心临床试验办公室(CTO)临床研究业务不可或缺的领导者 审判的最高收入者。 申请者寻求30%的工资支持，以支持他将继续致力于冠军、管理和 在MCW癌症中心进行NCI资助的临床试验，同时继续在基础上和改进 他自2017年以来领导的BMT/CT临床研究企业。作为BMT/CT疾病导向小组的主席 (DOT)，Hamadani为BMT/CT计划提供行政、临床和研究监督 研究组合，在癌症中心的14个成人DOT中持续积累最多的患者。 作为其机构领导职责的一部分，Hamadani协助BMT/CT方案的审查和激活 监督正在进行的临床试验的维护。BMT/CT计划将于#年取得成功 作为他多产的临床研究生涯的一部分，他构思、启动和进行了70多名研究人员- 作为地方或国家的首席研究员，发起、合作小组和行业赞助的试验。在 在国家层面上，Hamadani在血液和骨髓移植临床试验中发挥着积极和重要的作用 网络(BMT CTN)，这是由美国国立卫生研究院资助的一项倡议，进行大型多机构试验以改善蜂窝 治疗结果。作为几个BMT CTN试验的礼宾官员，其中三个试验正在积极招募患者， Hamadani负责网络协议的科学和监管监督。鉴于目标是 在未来几年扩大NCI资助的临床试验，包括那些属于BMT/CT计划的试验， Hamadani博士的目标是实施将扩大和维持BMT/CT临床试验研究的计划。支持 这一奖项将极大地促进这种努力，并使他能够继续致力于 为成功地在MCW癌症中心进行NCI资助的临床试验而付出的精力和努力。

PROJECT SUMMARY This application seeks partial salary support for a clinician scientist who is a highly accomplished clinical trialist in the Cancer Center at the Medical College of Wisconsin (MCW). Mehdi Hamadani, MD, the applicant for this Research Specialist Award, is currently a Professor of Medicine and the Medical and Administrative Director of the Cancer Center’s Clinical Blood and Marrow Transplantation and Cellular Therapy Program (BMT/CT). As a clinician who devotes two days per week to outpatient malignant hematology clinics and seven to eight weeks per year to inpatient service, Hamadani’s practice includes ~700 active cancer patients, with 147 new patients seen and 49 BMT and CT procedures provided to his clinic patients in 2021. At the same time, Hamadani is an indispensable leader of the clinical research operations of the Cancer Center’s Clinical Trials Office (CTO) and a top accruer to trials. The applicant seeks 30% salary support for the effort he will continue to devote to champion, administer and conduct NCI-funded clinical trials in the MCW Cancer Center, while continuing to build on and improve the BMT/CT clinical research enterprise he has led since 2017. As Chair of the BMT/CT Disease-Oriented Team (DOT), Hamadani provides administrative, clinical and research oversight for the BMT/CT program’s extensive research portfolio, which consistently accrues the most patients among the 14 adult DOTs at the Cancer Center. As part of his institutional leadership duties, Hamadani facilitates the BMT/CT protocol review and activation process and oversees maintenance of ongoing clinical trials. The successes of the BMT/CT program are due in part to his prolific clinical research career, having conceived, launched and conducted over 70 investigator- initiated, cooperative group, and industry-sponsored trials as local or national principal investigator. At the national level, Hamadani plays an active and instrumental role in the Blood and Marrow Transplant Clinical Trials Network (BMT CTN), an NIH-funded initiative that conducts large multi-institutional trials to improve cellular therapy outcomes. As protocol officer for several BMT CTN trials, three of which are actively enrolling patients, Hamadani is responsible for scientific and regulatory oversight of Network protocols. Given the targeted expansion of NCI-funded clinical trials in the coming years, including those that fall under the BMT/CT program, Dr. Hamadani aims to implement initiatives that will expand and sustain BMT/CT clinical trials research. Support provided by this award would significantly facilitate such efforts and allow him to continue to devote substantial energy and effort to the successful conduct of NCI-funded clinical trials in the MCW Cancer Center.